JP2020508303A5 - - Google Patents

Download PDF

Info

Publication number
JP2020508303A5
JP2020508303A5 JP2019544658A JP2019544658A JP2020508303A5 JP 2020508303 A5 JP2020508303 A5 JP 2020508303A5 JP 2019544658 A JP2019544658 A JP 2019544658A JP 2019544658 A JP2019544658 A JP 2019544658A JP 2020508303 A5 JP2020508303 A5 JP 2020508303A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019544658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508303A (ja
JP6929951B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2017/074365 external-priority patent/WO2018152687A1/en
Application filed filed Critical
Priority claimed from PCT/CN2018/076940 external-priority patent/WO2018153340A1/en
Publication of JP2020508303A publication Critical patent/JP2020508303A/ja
Publication of JP2020508303A5 publication Critical patent/JP2020508303A5/ja
Application granted granted Critical
Publication of JP6929951B2 publication Critical patent/JP6929951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019544658A 2017-02-22 2018-02-22 抗lag−3抗体およびその使用 Active JP6929951B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2017/074365 WO2018152687A1 (en) 2017-02-22 2017-02-22 Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CNPCT/CN2017/074365 2017-02-22
CNPCT/CN2017/088570 2017-06-16
CN2017088570 2017-06-16
PCT/CN2018/076940 WO2018153340A1 (en) 2017-02-22 2018-02-22 Anti-lag-3 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2020508303A JP2020508303A (ja) 2020-03-19
JP2020508303A5 true JP2020508303A5 (enExample) 2020-06-25
JP6929951B2 JP6929951B2 (ja) 2021-09-01

Family

ID=63253327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019544658A Active JP6929951B2 (ja) 2017-02-22 2018-02-22 抗lag−3抗体およびその使用

Country Status (12)

Country Link
US (2) US10577421B2 (enExample)
EP (1) EP3389702A4 (enExample)
JP (1) JP6929951B2 (enExample)
KR (2) KR102236259B1 (enExample)
CN (1) CN109475617B (enExample)
AU (1) AU2018226298B2 (enExample)
CA (1) CA3053989C (enExample)
IL (1) IL268734A (enExample)
NZ (1) NZ756678A (enExample)
SG (1) SG11201907561PA (enExample)
WO (1) WO2018153340A1 (enExample)
ZA (1) ZA201905790B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090005A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
CA3109999A1 (en) * 2018-08-21 2020-02-27 Abl Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CN110066334B (zh) * 2019-03-22 2020-03-10 南京医科大学 抗Galectin-3的全人源化单域抗体及应用
CN112010976B (zh) * 2019-05-29 2022-07-01 山东博安生物技术股份有限公司 抗lag3抗体及其用途
CN110320367A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院(广州呼吸中心) 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
KR102691493B1 (ko) * 2019-06-14 2024-08-05 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
AU2019456113A1 (en) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
WO2021013215A1 (zh) * 2019-07-23 2021-01-28 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
CN113004407B (zh) * 2019-12-20 2022-11-11 广东菲鹏制药股份有限公司 Lag3抗体及其应用
WO2021136392A1 (zh) * 2019-12-30 2021-07-08 上海海路生物技术有限公司 Lag-3抗体及其医药用途
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN116253797B (zh) * 2020-05-19 2024-05-14 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
CN115819585B (zh) * 2020-12-10 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
CN115490764B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Lgals3的表位肽及所述表位肽与热休克蛋白的复合物
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023178201A2 (en) * 2022-03-15 2023-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying anti-lag-3 agents
CN115819595B (zh) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 一种抗lag3纳米抗体及其制备方法与应用
WO2024189628A1 (en) * 2023-03-16 2024-09-19 Technion Research And Development Foundation Limited Lag-3 inhibition for enhanced antiviral immune response
EP4685152A1 (en) * 2023-03-20 2026-01-28 Kyungpook National University Industry-Academic Cooperation Foundation Peptide binding to lag-3 and use thereof
TW202509063A (zh) * 2023-08-21 2025-03-01 瑞士商百濟神州瑞士有限責任公司 用抗lag3、抗pd-1和化學療法治療食管癌
WO2025128836A1 (en) * 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies
WO2026059921A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10280221B2 (en) * 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
CN106029694A (zh) * 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
WO2015138920A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
AU2016298227B9 (en) * 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2017528476A5 (enExample)
JP2020500538A5 (enExample)
AR123305A2 (es) Proteínas de unión a antígeno
IL257281A (en) Anti-pd-1 antibodies and methods of using them
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
PH12021500002A1 (en) ANTIBODY-SIRPa ANTIBODY
JP2024175003A5 (enExample)
JP2021501579A5 (enExample)
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2022525377A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2015534982A5 (enExample)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2019536806A5 (enExample)
IL296682B2 (en) Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP2015508762A5 (enExample)
PE20170687A1 (es) Proteinas de enlace a cd127
JP2010536384A5 (enExample)
AR086579A1 (es) Proteinas de union a antigeno
JP2006512899A5 (enExample)
JP2011528902A5 (enExample)
PE20161033A1 (es) Proteinas de union al antigeno gitr
JP2011518125A5 (enExample)